Gastroenterology
Subcutaneous Golimumab Induces and Maintains Clinical Response and Remission in Patients with Moderate-to-Severe Ulcerative Colitis
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:18:27
- Mas informaciones
Informações:
Sinopsis
Two studies in the January issue of Gastroenterology show that subcutaneous golimumab induces and maintains clinical response and remission in patients with moderate-to-severe ulcerative colitis; Dr. Kuemmerle speaks to Dr. Brian G. Feagan
